Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Margaret Brown

Registered Nurse, Psychiatric/Mental Health Stoughton, MA Clinical Nurse Specialist

NPI 1649313941 CMS profile 11222380

294 Pleasant St Ste 205, Stoughton, MA 02072

Open in the dashboard

General payments

$13,199

646 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Margaret Brown of Stoughton, MA is reported in the CMS Open Payments database as having received $13,199 across 646 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Registered Nurse, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,463 209
2024 General $3,286 145
2023 General $2,591 138
2022 General $1,808 100
2021 General $1,051 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Margaret Brown
  • Registered Nurse, Psychiatric/Mental Health median
  • Middle half of Registered Nurse, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Margaret Brown were reported at $4,463. Among 280 Registered Nurse, Psychiatric/Mental Health profiles paid that year, the median was $140 and the middle half received between $43 and $515.

Show as a table
Year Margaret Brown Registered Nurse, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,051 $101 $31–$244 $132
2022 $1,808 $103 $36–$248 $149
2023 $2,591 $138 $45–$382 $160
2024 $3,286 $167 $39–$462 $164
2025 $4,463 $140 $43–$515 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ITI, Inc. $3,108 152 payments
  2. AbbVie, Inc. $2,043 96 payments
  3. Otsuka America Pharmaceutical, Inc. $1,524 74 payments
  4. Alkermes, Inc. $1,301 52 payments
  5. Teva Pharmaceuticals USA, Inc. $1,215 64 payments
  6. Vanda Pharmaceuticals Inc. $723 42 payments
  7. Lundbeck LLC $653 39 payments
  8. Janssen Pharmaceuticals, Inc $618 41 payments
  9. Sunovion Pharmaceuticals Inc. $534 29 payments
  10. E.R. Squibb & Sons, L.L.C. $407 15 payments
  11. Other $1,073 42 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,979 623 payments
  2. Education $221 23 payments
Products named General payments · program years 2021–2025
  1. CAPLYTA Psychiatry $2,155 111 payments
  2. VRAYLAR $1,360 60 payments
  3. REXULTI $1,083 59 payments
  4. CAPLYTA Psychiatry $953 41 payments
  5. LYBALVI $926 39 payments
  6. UZEDY $882 42 payments
  7. ARISTADA Cns $825 37 payments
  8. ARISTADA Cns $825 37 payments
  9. ARISTADA Cns $739 31 payments
  10. ARISTADA Cns $739 31 payments
  11. Other $6,826 327 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 54 drugs

Part D claims

2,926

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$713,984

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

20.8%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 82 $312,813
Caplyta Lumateperone Tosylate Brand 95 $159,409
Vraylar Cariprazine Hcl Brand 84 $134,775
Nuedexta Dextromethorphan Hbr/Quinidine Brand 12 $29,178
Aripiprazole Generic 96 $10,745
Adderall Dextroamphetamine/Amphetamine Brand 13 $9,540
Lamotrigine Er Lamotrigine Brand 41 $6,431
Paliperidone Er Paliperidone Brand 21 $4,218
Lamotrigine Generic 281 $3,443
Quetiapine Fumarate Generic 147 $3,245

The 10 drugs with the highest cost, of 54 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 4 billing codes

Paid by Medicare

$38,680

Medicare's payments for the services billed

Medicare patients

67

Average age 56

Services billed

394

34 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 67%
High blood pressure 49%
Arthritis 34%
Diabetes 27%
COPD 27%
Ischemic heart disease 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
$645 95 —
VRAYLAR
$593 84 —
FANAPT
$422 — —
REXULTI
$361 — —
UZEDY
$212 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

646 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, Psychiatric/Mental Health in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record